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ABSTRACT 
With an established role in cystic fibrosis and bronchiectasis, nebulized antibiotics are increasingly 
being used to treat respiratory infections in critically ill invasively mechanically ventilated adult 
patients. Although there is limited evidence describing their efficacy and safety, in an era of need for 
new strategies to enhance antibiotic effectiveness because of a shortage of new agents and 
increases in antibiotic resistance, the potential of nebulization of antibiotics to optimize therapy is 
considered of high interest, particularly in patients infected with multidrug-resistant (MDR) 
pathogens. This Position Paper of the European Society of Clinical Microbiology and Infectious 
Diseases provides recommendations based on the Grading of Recommendations Assessment, 
Development and Evaluation  (GRADE) methodology regarding the use of nebulized antibiotics in 
invasively mechanically ventilated adults, based on a systematic review and meta-analysis of the 
existing literature (last search July 2016). Overall, the panel recommends to avoid use of nebulized 
antibiotics in clinical practice, due to a weak level of evidence of their efficacy and the high potential 
for underestimated risks of adverse events (particularly, respiratory complications). Higher quality 
evidence is urgently needed to inform clinical practice. Priorities of future research are detailed in 
the second part of the Position Paper as a guidance for researchers in this field. In particular, the 
panel identified an urgent need for randomized clinical trials of nebulized antibiotic therapy as part 
of a substitution approach to treatment of pneumonia due to MDR pathogens. 
 
INTRODUCTION 
The administration of nebulized antibiotics is formally approved by regulatory bodies for the 
management of patients with bronchiectasis or cystic fibrosis (CF) [1]. However, the clinical 
challenges posed by extremely- or pan-drug resistant pathogens Gram-negative pathogens are 
causing significant concern for clinicians, creating situations reminiscent of the pre-antibiotic era. 
Therefore, despite lacking high-quality efficacy and safety data, clinicians worldwide are increasingly 
using antibiotic nebulization to optimize the treatment of respiratory infections in critically ill 
invasively mechanically ventilated adult patients [2, 3].  
The recommendations of this document, based on the highest-level available evidence, are intended 
to provide guidance for clinicians, nurses and respiratory therapists caring for adults under 
mechanical ventilation, as well as for antibiotic stewardship doctors and pharmacists. This Position 
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Paper consists of two parts: a) evidence-based recommendations developed using Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) methodology [4]; and b) 
discussion on future research priorities. 
 
METHODS  
Consensus Statement 
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for 
Infections in Critically Ill Patients (ESGCIP) received approval from the ESCMID Executive Committee 
to develop a Position Paper regarding the nebulization of antibiotics in critically ill invasively 
mechanically ventilated adult patients, using GRADE methodology to evaluate the available 
evidence.  
 
A Task Force was convened to develop this document, including critical care, respiratory and internal 
medicine physicians, anesthesiologists, clinical microbiologists, nurses, pharmacists and medical 
education specialists. Panel expert participants were suggested by the chair of the ESGCIP (JRe) and 
approved by the ESCMID Executive Committee, based on their prior clinical experience or on their 
expertise in clinical trials and publications, ensuring a true multidisciplinary approach. The 
systematic search of the literature, the meta-analysis and the application of the GRADE methodology 
were conducted in collaboration with the Iberoamerican Cochrane Centre (Barcelona, Spain). No 
industry input occurred into the development of this Position Paper and no industry representatives 
were present at any meeting. There was no industry funding for any aspect of this project.  
 
As a complement to this Position Paper providing evidence-based recommendations, another 
document compiling the key practical considerations of antibiotic nebulization was also written by a 
panel of experts [5] to help standardisation in their delivery in order to improve the safety in their 
administration.  
 
Definition of the review questions 
Every member of the panel of experts was asked to independently create a list of clinically-relevant 
questions to evaluate the effects of nebulized antibiotics. All questions were discussed and re-
evaluated by the panel until a consensus of review questions was reached. Eight questions were 
finally formulated by the panel, under the PICO (Population-Intervention-Comparison-Outcome) 
structure.  
 
Definition of the Population 
The targeted population was defined as adult critically ill patients with a respiratory infection, 
receiving support with invasive mechanical ventilation. The respiratory infections considered were 
ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). The panel 
of experts considered severe hospital-acquired pneumonia (HAP) requiring invasive mechanical 
ventilation to be equivalent to VAP for the purposes of evaluating the use of nebulized antibiotic 
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therapy. The susceptibility pattern of the pathogens was simplified to being susceptible or resistant 
(including multidrug- (MDR), extensively drug- or pandrug-resistant bacteria, as defined by the 
Center of Disease Control and Prevention [6]). Mechanical ventilation could be provided through any 
kind of invasive artificial airway (nasotracheal tube, orotracheal tube or tracheostomy).  
 
Definition of the Intervention  
The intervention was defined as the administration of nebulized antibiotics, such as ceftazidime, 
colistin or aminoglycosides. Antibiotic delivery needed to be performed with devices generating 
particles smaller than 5m of diameter (jet nebulizers, ultrasonic nebulizers or vibrating-mesh 
nebulizers) as is required to reach the lung parenchyma.  
Two different strategies of administration were considered clinically relevant (Table 1): 
1. Adjunctive strategy: nebulized colistin or aminoglycosides administered to patients already 
receiving intravenous (IV) colistin or aminoglycosides, added to standard first-line IV antibiotics (in 
comparison to patients also receiving the same IV therapy, but no nebulized antibiotics). 
2. Substitution strategy: nebulized colistin or aminoglycosides administered to patients not 
receiving IV colistin or aminoglycosides, but only first-line IV antibiotics (in comparison to patients 
receiving IV colistin or aminoglycosides – not nebulized - added to the first-line IV antibiotics). 
 
Definition of the Comparison  
The comparison was defined as the administration of IV antibiotics such as colistin or 
aminoglycosides, added to standard first-line IV antibiotics. 
 
Definition of the Outcomes 
In order to reach the most accurate evidence-based recommendations, the panel of experts 
considered it vital to evaluate both the efficacy and the safety of antibiotic nebulization. Therefore, 
they were asked to independently create a list of potentially relevant outcomes regarding both 
efficacy and safety. After a unique extensive list of outcomes was created, the panel were asked to 
rate all the proposed outcomes through a DELPHI questionnaire. Outcomes were classified as being 
“non-important” (rated 1 to 3), “important” (4 to 6) or “critical” (7 to 9). Only the “critical” outcomes 
(with a mean score equal to or more than 7), were evaluated in the systematic review and meta-
analysis [7]; the list of outcomes evaluated can be found in Appendix 1.  
 
To reach the maximal accuracy, each efficacy outcome was evaluated according to both the 
susceptibility pattern of the pathogen and the administration strategy. This contrasted the approach 
for evaluating the safety outcomes, as none of these were considered to be influenced by the 
susceptibility pattern of the pathogen, and as such, it was not taken into account for the safety 
analysis. Occurrence of cardio-respiratory complications was also not considered to be influenced by 
the administration’s strategy.  
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Inclusion & Exclusion Criteria 
Inclusion criteria were directly derived from the definitions of PICO components. The following 
population or types of intervention were excluded: 
- Population: neonatal and pediatric patients; adult patients without invasive mechanical 
ventilation support (therefore including non-invasive mechanical ventilation and high-flow 
oxygenotherapy); colonised patients, where colonisation was defined as presence of purulent 
tracheal secretions without infectious clinical signs and radiological infiltrates; patients with cystic 
fibrosis or other non-cystic fibrosis bronchiectasis were excluded as they were considered to have 
particular characteristics deserving a separate evaluation; patients with particular characteristics 
such as burned patients, patients receiving support with renal replacement therapies and/or 
cardiopulmonary support with extracorporeal life support devices were also excluded from the 
study, due to the lack of knowledge on the impact these techniques might have in the technique 
being evaluated.  
- Intervention: nebulisation delivered with devices other than jet nebulisers, ultrasonic 
nebulisers and/or vibrating-mesh nebulisers, where the device would be likely to produce particles 
larger than 5 m in diameter and therfore less likely to reach the lung parenchyma; other practices 
such as tracheal instillation (either manually or with a pneumatic pump) were also rejected.  
 
Systematic Review & Meta-analysis 
Herewith, we provide general information on the methodology used. For further detail on the 
characteristics of the included studies, and evaluation of quality and risk of bias, etc., we suggest 
referring to the systematic review and meta-analysis reported elsewhere [7].  
 
Systematic search of the literature 
After the definition of the PICO questions and exclusion criteria, a search strategy was created (list of 
terms detailed in the Appendix 2). A systematic search was conducted in three different databases 
(MEDLINE Database, EMBASE and The Cochrane Library) in June 2014 and repeated in March 2015 
and in July 2016. No restrictions of language, time or type of publication were imposed. A total of 
1435 studies were identified.  
 
Study selection 
Three authors (SB, GP and CSL) independently assessed all the studies identified in the literature 
search by screening their titles and abstracts. Disagreements between reviewers were resolved by 
consensus. In case of persistent disagreement, a fourth independent reviewer (IS) determined the 
eligibility of the study. Authors of articles considered for rejection due to lack of information (e.g. 
type of device used), were contacted to provide further details. Only randomized-controlled trials 
(RCT), observational studies and case series evaluating efficacy and/or safety of the technique were 
eligible to be included in the meta-analysis. Review articles, expert opinion articles, and other 
articles having not undergone a peer-review process, like abstracts from congresses, were manually 
rejected. After assessment for inclusion, manual adjusting for duplicates and revision of the 
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manuscripts in relation to our inclusion and exclusion criteria, only 11 studies were included in the 
meta-analysis [8-18].  
A final search was repeated in July 2016, finding only one additional RCT [19] that met the criteria 
for its inclusion in our meta-analysis. This paper was only considered eligible for inclusion in the 
analysis of safety outcomes (and not in the analysis of efficacy outcomes) due to its high risk of bias: 
an intention-to-treat analysis of a non-inferiority study, single blinded and with a loss of patients to 
follow up of 18.7 %. 
 
Data Items & Collection  
Based on the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions 
[20], a data sheet was developed for data extraction for each included study. Study design, inclusion 
& exclusion criteria of patients, administration strategy, drugs and type of nebulizer used, main and 
secondary outcomes evaluated and adverse events reported were all collected for each study in an 
individual data sheet. Data extraction was performed by one of the authors ( SL) and checked by 
and independent reviewer (SP). Authors of articles with relevant non-reported or unclear data were 
contacted to provide further information.  
 
Risk of bias assessment 
Risk of bias for randomized controlled trials and observational studies was evaluated based on the 
recommendations of the Cochrane Handbook for Systematic Reviews of Interventions [20] by one of 
the authors (CSL) and checked by a second independent reviewer (SP). Details are reported 
elsewhere [7]. 
 
Statistical analysis 
Analysis of all outcomes was performed according to the design of the study, as reported in March 
2017 [7]. Pooled evaluation of RCT and observational studies was also performed for each outcome 
due to the small sample size of included studies, so a potential existence of clinically significant 
trends could be detected. Risk ratio (RR) and odds ratio (OR) were used for the evaluation of binary 
outcomes for RCTs and observational studies respectively. Risk difference (RD) was also used 
whenever necessary. Mean difference (MD) was used for the evaluation of continuous outcomes. All 
statistical measures were calculated with a 95% confidence interval (CI). Random-effects meta-
analysis through the Mantel-Haenszel model approach was performed to obtain pooled study results 
of RCTs and observational studies. Higgins I2 test was predefined to quantify heterogeneity (I2 ≤ 25% 
for low heterogeneity; 25% ≤ I2 ≤ 50% for moderate heterogeneity; I2 50% for high heterogeneity). 
Meta-regression was not performed given the low number of studies included in the meta-analysis. 
All statistical analyses were performed using Review Manager (RevMan) version 5.3 (Nordic 
Cochrane Centre, Cochrane Collaboration, Denmark, 2014).  
 
Development of Recommendations 
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 The results of the systematic review and meta-analysis were evaluated under the GRADE 
methodology [4] to achieve an evidence-based recommendation for each one of the initial PICO 
questions.  
Values and preferences relating to both patients and costs were taken into account by the panel of 
experts. Regarding the values and preferences of the patients, the Task Force considered that none 
of the interventions (nebulized or IV administration) could be considered particularly uncomfortable 
or invasive for the patients. Therefore, given the non-significant difference, this scenario was 
considered not value-sensitive. Regarding the costs and resource use, no economic studies were 
identified assessing the cost of antibiotic nebulization. The panel of experts estimated the cost of 
nebulized antibiotics to be similar to the cost of average intravenous antibiotic therapy. However, 
nebulized antibiotics are usually added to systemic therapy, therefore the cost of the total therapy 
would be higher.  
 
 
EVIDENCE-BASED RECOMMENDATIONS 
 
Ventilator-associated Pneumonia (VAP) 
 
1. VAP caused by Resistant Pathogens 
 
1.1. Adjunctive Strategy: In mechanically ventilated patients already receiving conventional IV 
therapy, including colistin or aminoglycosides, for a VAP caused by resistant pathogens, should 
nebulized antibiotics such as colistin or aminoglycosides be used, as adjunctive therapy to systemic 
antibiotics, as compared to absence of local treatment, to improve clinical outcome? 
Summary of the Evidence 
Our systematic review identified one RCT [8] and three observational studies [9, 10, 11], involving a 
total of 458 patients, evaluating the efficacy of nebulized antibiotics under this administration 
strategy for the treatment of VAP caused by resistant organisms. Two studies [8, 9] employed a 
vibrating mesh nebulizer, one [10] used both jet and vibrating-mesh devices, and one [11] both jet 
and ultrasonic devices.  
No significant difference in clinical resolution rates were observed in the RCT (48 patients; OR=1.30; 
95%CI 0.22-7.55). The meta-analysis of the observational studies showed higher rates of clinical 
resolution in the group of patients receiving nebulized antibiotics (389 patients; OR=0.51; 95%CI 
0.34-0.77; I2=0%), significantly shorter duration of MV support (303 patients; 3.72 days less; 95%CI 
from -5.86 to -1.59 days; I2=0%) and significantly lower VAP-related mortality (181 patients; OR=0.5; 
95%CI 0.26-0.96; I2=0%), even though all-cause mortality did not differ significantly. No significant 
differences were seen for duration of ICU stay or development of superinfections. No evidence was 
provided for the emergence of resistant strains.  
The overall quality of evidence is very low, due to serious imprecision and indirectness of the results 
for the majority of the outcomes. The safety analysis evidenced a higher incidence of respiratory 
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complications (low quality of evidence) associated with nebulization, and no differences in systemic 
toxicity (nephrotoxicity and neurotoxicity; very low quality of evidence).  
 
Recommendation 
We suggest avoiding the use of nebulized antibiotics such as colistin or aminoglycosides, added to 
conventional IV antibiotic therapy already including IV colistin or aminoglycosides for the treatment 
of VAP caused by resistant pathogens as standard clinical practice.  
Weak recommendation. Very low quality of evidence. 
 
Remark: We recommend avoiding their use particularly in patients with severe hypoxemia 
(PaO2/FiO2 ratio < 200) or having shown signs of poor pulmonary reserve, tending to rapid lung de-
recruitment.  
 
Rationale for the Recommendation 
Evidence obtained from observational studies suggested that the addition of nebulized antibiotics 
such as colistin or aminoglycosides to a conventional IV antibiotic therapy already involving these 
antibiotics, might be effective against VAP caused by resistant pathogens, mainly in terms of clinical 
resolution and duration of mechanical ventilation support. The weak quality of this evidence was 
balanced against the fact that nebulisation of antibiotics was associated with higher risk of 
respiratory complications. As a conclusion, the panel of experts decided to recommend their 
avoidance in clinical practice.  
 
 
1.2. Substitution Strategy- In mechanically ventilated patients already receiving conventional IV 
therapy, for a VAP caused by resistant pathogens, should nebulized antibiotics such as colistin or 
aminoglycosides be exclusively used, as compared to conventional IV therapy with additional IV 
colistin or aminoglycosides, to improve clinical outcome? 
 
Summary of the Evidence 
Only one observational study [12] addressed the administration of nebulized antibiotics under this 
strategy, in cancer patients. A jet nebulizer was the device used in this study involving 32 patients. 
Higher rates of clinical resolution were associated with the administration of nebulized antibiotics 
(OR=9.53; 95%CI 1.85-49.2), but no significant differences were found for the rest of the efficacy 
outcomes analysed, duration of mechanical ventilation support and ICU stay. The overall quality of 
the evidence was very low due to the serious indirectness and very serious imprecision of the results 
for all the outcomes. The safety evaluation determined that nebulized antibiotic administration was 
associated with a higher incidence of respiratory complications (low quality of evidence) and 
reduced nephrotoxicity (low quality of evidence) associated to their use under the substitution 
strategy. No differences were observed in terms of other systemic toxicities.  
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Recommendation 
We suggest avoiding  the use of nebulized antibiotics such as colistin or aminoglycosides instead of 
their IV administration for the treatment of VAP caused by resistant pathogens as standard clinical 
practice 
Weak recommendation. Very low quality of evidence. 
 
Remark: We recommend avoiding their use particularly in patients experiencing severe hypoxemia 
(PaO2/FiO2 ratio < 200) or demonstrating signs of poor pulmonary reserve, tending to rapid de-
recruitment.  
 
Rationale for the Recommendation 
Despite the weak evidence suggesting that the administration of nebulized antibiotics such as 
colistin or aminoglycosides instead of the administration of those IV antibiotics might be a good 
option for the treatment of VAP caused by resistant pathogens mainly in terms of clinical resolution 
and less occurrence of nephrotoxicity, the recommendation of the guideline panel was to avoid their 
use in standard clinical practice. The rationale for this recommendation was balancing the higher 
rates of respiratory complications associated with the use of nebulized antibiotics against the low 
quality evidence suggesting potential benefits of their use.  
 
2. VAP caused by Antibiotic-Susceptible Pathogens 
 
2.1. Adjunctive Strategy: In mechanically ventilated patients already receiving conventional IV 
therapy, including colistin or aminoglycosides, for a VAP caused by antibiotic-susceptible pathogens, 
should nebulized antibiotics such as colistin or aminoglycosides be used, as adjunctive therapy to 
systemic antibiotics, as compared to absence of local treatment, to improve clinical outcome? 
 
Summary of the Evidence 
No evidence was found regarding the use of nebulized antibiotics such as colistin or 
aminoglycosides, added to conventional IV antibiotic therapy already including IV colistin or 
aminoglycosides for the treatment of VAP caused by susceptible pathogens in invasively 
mechanically ventilated patients, in comparison to the use of conventional IV antibiotic therapy 
alone.  
 
Recommendation 
We recommend avoiding the use of nebulized antibiotics such as colistin or aminoglycosides, added 
to conventional IV antibiotic therapy already including IV colistin or aminoglycosides for the 
treatment of VAP caused by antibiotic-susceptible pathogens in clinical practice.  
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Strong recommendation. No evidence available. 
 
Rationale for the Recommendation 
Due to the lack of available evidence, no recommendation should be made on the use of nebulized 
antibiotics such as colistin or aminoglycosides, added to conventional IV antibiotic therapy already 
including IV colistin or aminoglycosides for the treatment of VAP caused by susceptible pathogens in 
invasively mechanically ventilated patients. However, balancing this absence of evidence versus 
evidence causing a higher risk of respiratory adverse effects, the panel considers it to be consistent 
and responsible to recommend the avoidance of this treatment strategy against VAP caused by 
susceptible pathogens. 
 
2.2. Substitution Administration Strategy- In mechanically ventilated patients with VAP caused by 
antibiotic-susceptible pathogens, should nebulized antibiotics such as colistin or aminoglycosides be 
used, instead of systemic IV therapy, to improve clinical outcome? 
 
Summary of the Evidence 
One RCT [13] evaluating the use of nebulized antibiotics (aminoglycosides and ceftazidime, without 
other concomitant IV antibiotics) to treat VAP caused by antibiotic-susceptible pathogens, in 
comparison to the use of those IV antibiotics, was considered to have an administration strategy 
equivalent to the substitution strategy, and therefore included in our analysis. A vibrating-mesh 
nebulizer was the device used in this trial of 40 patients.  
 
No significant differences were observed for clinical resolution, mortality, duration of mechanical 
ventilation or ICU stay, and occurrence of superinfection. The fact that 50% of the pathogens in the 
group receiving IV antibiotics became intermediate or resistant, in contrast to the susceptible strains 
that caused new growth or persistence of the infection in the group receiving nebulized antibiotics, 
might lead one to consider nebulization of antibiotics for preventing the emergence of resistant 
strains, but no further evidence is available on this particular outcome. The overall quality of the 
evidence is very low due to serious indirectness and very serious imprecision of the results for all the 
efficacy outcomes. The safety evaluation of nebulization was associated with a higher incidence of 
respiratory complications (low quality of evidence) and a reduced occurrence of nephrotoxicity (low 
quality of evidence). No differences were observed in terms of other systemic toxicities.  
 
Recommendation 
We suggest avoiding the use of nebulized antibiotics such as colistin or aminoglycosides instead of 
their IV administration for the treatment of VAP caused by antibiotic-susceptible pathogens in 
clinical practice.  
Weak recommendation. Very low quality of evidence. 
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Remark: We recommend avoiding their use particularly in patients undergoing a severe hypoxemia 
(PaO2/FiO2 ratio < 200) or having shown signs of poor pulmonary reserve, tending to rapid de-
recruitment.  
 
Rationale for the Recommendation 
Due to the lack of evidence supporting efficacy of nebulized antibiotics such as colistin or 
aminoglycosides administered in place of those same IV antibiotics for the treatment of VAP caused 
by antibiotic-susceptible pathogens, and balancing this lack of efficacy with the evidence on higher 
rates of respiratory complications associated to their use, the guideline panel agreed to suggest 
avoiding use of nebulized antibiotics in this context. 
 
 
Ventilator-associated Tracheobronchitis (VAT) 
 
1.1. Adjunctive Strategy: In mechanically ventilated patients already receiving conventional IV 
antibiotic therapy for ventilator-associated tracheobronchitis (VAT), should nebulized antibiotics be 
used, as compared to absence of local treatment, to improve clinical outcome?  
 
Summary of the Evidence 
Our systematic review identified only 2 RCTs [14-15], involving a total of 85 patients. The device 
used for nebulization was a jet nebulizer in both studies. Both trials defined clinical resolution only 
as an improvement of the Clinical Pulmonary Infection Score, and included also patients meeting 
clinical criteria for the diagnosis of a VAP. 
No significant differences were found either in mortality or duration of mechanical ventilation nor in 
the occurrence of systemic adverse events such as nephrotoxicity. No evidence was provided for the 
remaining predefined outcomes (clinical resolution, length of ICU stay, emergence of superinfection, 
existence of other adverse events such as respiratory complications).  
The meta-analysis of the trials showed a significant reduction in the emergence of resistant strains in 
surveillance cultures in patients receiving nebulized antibiotics added to the conventional IV therapy 
(70 patients; RR=0.18; 95% CI, 0.05 -0.64; I2=0%; 328 for every 1000 treated patients, with a range 
from 144 to 380; moderate quality of evidence), as well as an increase in the clinical resolution as 
per improvement of the Clinical Pulmonary Infection Score (high heterogeneity: I2=90%; very low 
quality of evidence). The overall quality of the evidence is low due to the very serious imprecision 
and serious indirectness of the results.   
 
Recommendation 
We suggest avoiding the use of nebulized antibiotics added to conventional IV antibiotic therapy for 
the treatment of patients with VAT in clinical practice.  
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Weak recommendation. Low quality of evidence. 
 
Rationale for the Recommendation 
The panel concluded that owing to significance heterogeneity, small sample sizes and inconsistent 
effects, the available evidence quality was low. Therefore, the only potential benefit of adding 
nebulized antibiotics to the systemic therapy would be a decrease in the emergence of resistant 
strains, which should still be confirmed with a period of follow-up of the patients greater than 28 
days after commencing therapy.  
 
1.2. Substitution Administration Strategy:- In mechanically ventilated patients with VAT, should 
nebulized antibiotics be used, as compared to the use of conventional IV antibiotic therapy, to 
improve clinical outcome? 
 
Summary of the Evidence 
No evidence was found regarding the use of nebulized antibiotics for the treatment of VAT in 
invasively mechanically ventilated patients, as a sole therapy, in comparison to the use of 
conventional IV antibiotic therapy.  
 
Recommendation 
We recommend avoiding the use of nebulized antibiotics as a single therapy, instead of conventional 
IV antibiotic therapy, for the treatment of patients with VAT in clinical practice.  
Strong recommendation. No evidence available. 
 
Rationale for the Recommendation 
There is no available evidence for the use of nebulized antibiotics for the treatment of VAT as a sole 
therapy, instead of treatment with IV antibiotics. However, this absence of evidence leads the 
guideline panel to consider it consistent and responsible to not recommend nebulized antibiotics for 
the treatment of VAT.  
 
 
Non-bacterial Respiratory Infections 
 
1. In mechanically ventilated patients already receiving conventional antiviral therapy for a viral 
respiratory infection, should nebulized antivirals be used, in comparison to conventional antiviral 
therapy, to improve clinical outcome? 
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Summary of the Evidence 
No evidence was found regarding the use of nebulized antivirals for the treatment of viral 
respiratory infections in invasively mechanically ventilated patients. Some case series and reports 
exist regarding nebulization of zanamivir, which is not approved for nebulization. In fact, an FDA 
alert from October 2009 reported the death of a person affected with influenza, who had received 
zanamivir powder for inhalation through a nebulizer. According to the manufacturer, lactose sugar in 
the formulation increases the risk of obstruction of the circuit.  
 
Recommendation 
We recommend avoiding the use of nebulized antivirals for the treatment of patients with a viral 
respiratory infection in clinical practice.  
Strong recommendation. No evidence available. 
 
Rationale for the Recommendation 
Due to the lack of available evidence, no recommendation should be made on the use of nebulized 
antivirals for the treatment of viral respiratory infections. However, this absence of evidence leads 
the panel to consider it consistent and responsible to recommend avoiding nebulization of antivirals 
in clinical practice. 
 
2. In mechanically ventilated patients already receiving conventional antifungal therapy for a 
fungal respiratory infection, should nebulized antifungals be used, in comparison to conventional 
antifungal therapy, to improve clinical outcome? 
Summary of the Evidence 
No evidence was found regarding the use of nebulized antifungals for the treatment of fungal 
respiratory infections in invasively mechanically ventilated patients. Only one case series [21] 
reported experience with nebulization of Amphotericin B Lipid Complex (ABLC) to 32 
immunosuppressed oncological patients as adjunctive treatment to systemic antifungals. Only 8 of 
these patients were under mechanical ventilation. Mild respiratory complications (without 
specifying if they occurred to the patients under mechanical ventilation), were reported. 
 
Recommendation 
We recommend avoiding the use of nebulized antifungals for the treatment of patients with a fungal 
respiratory infection in clinical practice.  
Strong recommendation. No evidence available. 
 
Rationale for the Recommendation 
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Due to the lack of available evidence, no recommendation should be made on the use of nebulized 
antifungals for the treatment of fungal respiratory infections. However, this absence of evidence 
leads the guideline panel to consider it consistent and responsible to recommend the avoidance of 
their use in clinical practice 
 
 
FUTURE RESEARCH PRIORITIES 
 
Critical analysis of the existing literature regarding nebulization of antibiotics in invasively 
mechanically ventilated patients identified an important gap in the knowledge about it. After 
evaluating the evidence, we concluded that no recommendations supporting the standard clinical 
use of nebulized antibiotics could be reached, mainly due to the lack of strength of the existing 
studies and to the risk of severe adverse events, especially respiratory complications.  
In addition, important gaps exist in terms of the dosages and devices used, with further 
experimental PK/PD studies required. Even more, some widely-variable clinical practices and 
technical aspects of the nebulization process are based on a rationale yet to be justified. Specific 
studies are also required in both the neonatal and pediatric populations. Future research is urgently 
needed to address this lack of data and generate a higher quality of evidence.  
 
Experimental research priorities 
 
Devices 
Experimental in vivo studies comparing the lung parenchyma delivery between the different types of 
nebulizers should be performed in order to establish their optimal indications. At present, there is a 
single available in vivo experimental study comparing lung deposition of antibiotic particles delivered 
through ultrasonic and vibrating mesh nebulizers [22]. Positioning of the devices in the circuit should 
be particularly evaluated, as well as the potential benefit of breath-enhanced jet nebulizers 
synchronizing nebulization with inspiration. 
 
Anti-infective drugs 
A limited number of PK/PD experimental in vivo studies have been published on nebulized amikacin, 
ceftazidime and colistin [22-29]. Some important issues such as the potential benefit of combining IV 
administration and nebulization of the same antibiotic have not been assessed and should be an 
important area of future research. The possibility of nebulizing vancomycin to treat VAP caused by 
methicillin-resistant Staphylococcus aureus requires future experimental PK/PD in vivo studies 
before clinical use. The same type of experiments should also be performed to assess the potential 
benefit of nebulizing anti-viral and anti-fungal medication (specifically formulized for nebulization). 
Although they are technically complicated, such studies evaluating the optimal dosage regimens of 
various anti-infective agents are recommended to ensure optimal clinical use. 
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Clinical research priorities 
 
Study design  
As demonstrated in our meta-analysis [7], very limited RCT data is available, and the sample size of 
the current studies is too small. Results from various observational studies suggest that nebulized 
antibiotics may be effective for the treatment of respiratory infections. However, even the highest 
quality observational studies are never able to take into account all possible confounders, as they 
might be unknown or difficult to measure [30], especially with a retrospective approach. Thus, RCTs 
are urgently needed to increase the current level of evidence of the efficacy and safety of nebulizes 
antibiotics. Even more, in the coming years it is imperative to have more data on the drugs, dosage 
regimens and optimal durations of the therapy, its indications and appropriate administration 
strategy, and whether combinations of antibiotics may offer additional advantages.  
 
The panel acknowledges that a significant source of heterogeneity amongst the published studies in 
the area relates to inconsistencies in clinical definitions for diagnosis of the infection and of its 
resolution. Lack of gold standard for both VAT and VAP definitions (with great variability in VAT) 
require to consider both diagnoses, with microbiology and tests of cure specific to the therapy for 
each respiratory infection. Further studies using standardized definitions, as well as pre-defined 
clinically meaningful outcomes such as mechanical ventilation duration, and measurement of the 
effects on bacterial burden are required. Resolution of fever and hypoxemia in VAP is early (median 
within 72h) whereas pre-defined assessment at 8 or 15 days ignore potential meaningful differences 
between two strategies of therapy. Thus, for the particular outcome of resolution of the infection, 
the panel would recommend evaluating the “time to clinical resolution”, instead of the existence of 
a clinical resolution at a pre-defined point, to identify potential advantages of nebulization in VAP 
caused by MDR organisms.  
 
Currently, there are ongoing phase III clinical trials (e.g., NCT01969799, NCT01799993) regarding 
aerosolized antimicrobials using novel integrated delivery technologies, such as Amikacin inhale, 
BAY41-6551 (NKTR-061) or PARI GMBH (Stamburg, Germany) [31]. Whether they will add value to 
the current delivery systems remains unknown.  Detailed information on ongoing trials is shown in 
Table 2. 
An urgent need of randomized clinical trials under the substitution administration strategy for 
treatment of pneumonia due to MDR pathogens exists and the panel identify this subset as a priority 
in research. 
 
Safety evaluation 
Safety is an overriding concern regarding nebulization of antibiotics. Even though evidence seems to 
suggest that they are less harmful than IV antibiotics regarding the occurrence of nephrotoxicity, the 
existence of a higher risk of respiratory complications is an important concern, particularly as this 
risk seems to increase when they are administered to patients with severe hypoxemia. These are 
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patients most likely to receive nebulized antibiotics due to the severity of their infection. Standards 
to prevent use of agents that are not proven and ensure patients’ safety should be similar to those 
for systemic administration. Specific safety evaluations and standardized administration techniques 
[5] are needed to properly establish their limitations and should be an integral part of future RCTs.  
  
Nebulized colistin 
A high priority should be given to RCTs comparing the treatment efficacy of systemic administration 
and nebulization of high doses of colistin in VAP (and VAT) caused by MDR Gram-negative 
pathogens. The rationale for combining IV and nebulized colistin to treat VAP is debatable, although 
it is a widely used clinical practice in spite of safety concerns. IV colistin has a slow and limited 
pulmonary diffusion but has a significant renal toxicity. Nebulized colistin has a limited systemic 
diffusion, which provides the possibility of achieving high lung tissue concentrations without 
systemic toxicity [32, 23, 33]. Combination of both routes of administration likely results in a higher 
risk of renal toxicity without increasing significantly lung tissue concentration, although the 
distribution of nebulized throughout different segments of the lung remains unclear. 
 
Nebulized aminoglycosides 
PK/PD experimental and clinical studies clearly demonstrate a very limited diffusion of IV 
aminoglycosides into the lung parenchyma [34-38]. Two RCTs have demonstrated that the addition 
of IV aminoglycosides to cephalosporins does not increase the recovery rate of HAP [39, 40]. Three 
meta-analyses have recommended avoidance of the use of IV aminoglycosides to treat HAP and VAP 
[41-43]. In contrast, PK/PD experimental studies have reported high lung tissue concentrations of 
nebulized amikacin [24, 25] and suggested potential synergy when associated with fosfomycin [44]. 
Therefore, RCTs comparing the treatment efficacy of the IV administration and the nebulization of 
high doses aminoglycosides in VAP (and VAT) caused by susceptible Gram-negative bacteria is a 
second-line research priority. Similar to colistin, the PK/PD rationale for combining both 
administration routes is weak. Intravenous amikacin has a limited pulmonary diffusion and has a 
significant systemic renal toxicity. On the other hand, nebulized amikacin rapidly diffuses into the 
systemic circulation, potentially exposing the patient to systemic toxicity [24, 25, 32] with plasma 
concentration monitoring advised. Combining both routes of administration likely results in an 
increased risk of renal toxicity and does not appear as a safe practice. 
 
Other antibiotics 
Most research in mechanically ventilated patients has been conducted with aminoglycosides and 
colistin. Ceftazidime has been used in a few studies [13]. The panel suggest the need to address 
research using other antibiotics, such as ceftazidime/avibactam or other cephalosporins. 
 
Emergence of resistance 
This is a key observation that is incompletely elucidated and is a vital research priority in the area. 
Emergence of resistance cannot be assessed only based in samples of patients already receiving 
antimicrobials and requires long-term follow-up, after completion of nebulization. Additionally, 
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further information is required on the impact of nebulized antibiotic therapy on the lung and airway 
microbiome, not just MDR pathogen emergence. There is emerging evidence that indicates that 
changes in the innate microbiome increase the likelihood of future infections, including in ventilated 
patients. However, it is unknown how quickly the damage is incurred to the microbiota and how 
long does it lasts. It is also unclear whether nebulized therapy is beneficial or whether it increases 
damage to the airway microbiota.  While there is little data addressing this, it is recommended as an 
important future research direction.  
 
Regulatory and clinical issues. 
There are significant challenges in demonstrating superiority in clinical registration trials for new 
antibiotics whose main activity is likely to be against MDR pathogens. These include the patient 
population under study, the end-points to be studied and the choice of comparator. The most widely 
accepted outcome measure is resolution of infection, usually expressed as “Test of Cure”. This may 
be a microbiological evaluation or a clinical evaluation of patient improvement based on the 
clinician’s opinion or scores. “Time to resolution” is a recommended outcome variable because there 
is little room for improvement to demonstrate superiority using conventional regulator end-points. 
To address the increasing threat of MDR pathogens and provide incentive for greater investment in 
antibiotic development, regulators have recognised the importance of pathogen-based studies. 
Whilst these remain operationally challenging to recruit for, they do offer an opportunity to better 
study aerosolized antibiotics in a population where it is most likely to have the greatest utility, and 
therefore, value. 
Unfortunately, no information was available on costs. Pharmaco-economic studies, adapted to 
regional differences, should be performed to assess the cost-effectiveness of these strategies. At the 
reimbursement approval stage, some degree of cost/benefit, or cost-effectiveness assessment is 
considered at a national or regional level by health technology assessment agencies.  
 
CONCLUSIONS. 
Nebulisation of antibiotics in mechanically ventilated adults with respiratory infections is a practice 
that is increasingly used, despite a lack of standardization and limited evidence on the associated 
efficacy and safety [2-3]. Based on a prior systematic review and meta-analysis [7], this ESCMID 
panel does not support the use of nebulization of antibiotics in any of the scenarios assessed 
because the available evidence is weak and heterogeneous (and in some scenarios entirely absent). 
Further research to achieve high-quality evidence is urgently needed.  
Given that aerosolization of antibiotics is an active area of research, and the literature is emerging 
[45-47], the meta-analysis should be updated periodically. Thus, these recommendations may 
change in the future as new study data becomes available. 
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LIST OF ABBREVIATIONS 
 
CF  cystic fibrosis 
GRADE  Grading of Recommendations, Assessment, Development and Evaluation 
ESCMID European Society of Clinical Microbiology and Infectious Diseases 
ESGCIP  ESCMID Group for Infections in Critically Ill Patients 
VAT  Ventilator-associated tracheobronchitis 
VAP  Ventilator-associated pneumonia 
HAP  Hospital-acquired pneumonia 
MDR  Multidrug-resistant  
IV  Intravenous 
RCT  Randomized-controlled trials 
RR  Risk ratio 
OR  Odds ratio 
RD  Risk difference 
MD  Mean difference  
CI  Confidence interval 
 
 
Appendix 1. List of pre-defined evaluated outcomes 
 
Efficacy Outcomes: 
 
- Clinical resolution (yes/no; after 8 days of treatment) if one or more of the following occurred: 
Removal of vital support (ventilation, vassopressors) 
Improvement of daily organ failure score  
Improvement of PaO2/FiO2 ratio 
Inflammatory parameters decrease (C-reactive protein and/or procalcitonin) 
 
- 30-day mortality (yes/no) 
- Duration of mechanical ventilation (days) 
- Duration of ICU stay (days) 
- Occurrence of superinfection (yes/no) 
- Emergence of resistant strains (yes/no) 
 
Safety Outcomes: 
 
- Systemic toxicity (yes/no; especially nephrotoxicity) 
- Cardiorespiratory complications (yes/no; including hypoxemia, cough, bronchoconstriction, lung injury 
or acute respiratory distress syndrome, problems with the nebulisation system such as obstruction of 
the expiratory filter; arrythmias, cardiorespiratory arrest). 
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Appendix 2. List of terms of the search strategy. 
 
#1 "Aerosols" [Mesh] 
#2 "Nebulizers and Vaporizers" [Mesh]  
#3 nebul*[tiab]  
#4 aerosol*[tiab] 
#5 vaporiz*[tiab]  
#6 inhal*[tiab]  
#7 pulmonary delivery*[tiab]  
#8 atomiz*[tiab]  
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 
#10 "Anti-Bacterial Agents" [Mesh]  
#11 antimicrobial*[tiab]  
#12 antibacterial*[tiab]  
#13 anti-bacterial*[tiab]  
#14 antibiotic*[tiab]  
#15 bacterio*[tiab] 
#16 antiviral*[tiab]  
#17 antifungal*[tiab]  
#18 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17  
#19 "Pneumonia, Ventilator-Associated" [Mesh]  
#20 ventilator associated pneumonia*[tiab]  
#21 vap[tiab]  
#22 nosocomial pneumonia*[tiab]  
#23 Hospital-acquired pneumonia*[tiab]  
#24 hap[tiab]  
#25 respiratory tract*[tiab] 
 #26 ventilator associated tracheobronchitis*[tiab]  
#27 vat[tiab]  
#28 viral respiratory infection*[tiab]  
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#29 fungal respiratory infection*[tiab]  
#30 ventilat*[tiab] 
#31 intubat*[tiab]  
#32 lung infect*[tiab]  
#33 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR 
#31 OR #32 
#34 #9 AND #18 AND #33 
#35 colistin*[ti]  
#36 polymyxin*[ti]  
#37 amikacin*[ti]  
#38 gentamicin*[ti]  
#39 tobramycin*[ti]  
#40 aminoglycoside*[ti]  
#41 ciprofloxacin*[ti] 
#42 ribavirin*[ti]  
#43 zanamivir*[ti]  
#44 oseltamivir*[ti]  
#45 amphotericin*[ti]  
#46 pentamidin*[ti]  
#47 caspofungin*[ti]  
#48 fluconazole*[ti] 
 #49 posaconazole*[ti]  
#50 voriconazole*[ti]  
#51 vancomycin*[ti] 
#52 meropenem[ti]  
#53 ertapenem[ti] 
#54 imipenem*[ti]  
#55 doripenem*[ti] 
#56 #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR 
#47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54  OR #55 
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#57 #18 OR #56  
#58 #9 AND #33 AND #57  
#59 #34 OR #58 
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Table 1. Different strategies considered regarding the administration of nebulized antibiotics 
 
 
Strategy Intervention Comparison 
Adjunctive  First-line IV antibiotics 
+ 
IV colistin / aminoglycosides 
+ 
Nebulised colistin / aminoglycosides 
First-line IV antibiotics 
+ 
IV colistin / aminoglycosides 
Substitution  First-line IV antibiotics 
+ 
Nebulised colistin / aminoglycosides 
First-line IV antibiotics 
+ 
IV colistin / aminoglycosides 
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Table 2-  Nebulized Antibiotics Ongoing Clinical Trials.  
Sources: www.clinicaltrials.gov and www.clinicaltrialsregister.eu 
 Accessed December 1st, 2016. 
 
Title – Reference Sponsors - 
collaborators 
Intervention Comparator Primary 
outcome 
Secondary 
outcome 
Investigator 
Nebulized and 
intravenous 
colistin in 
ventilator 
associated-
pneumonia 
(COLIVAP) - 
NCT02906722 
Assistance 
publique - 
Hôpitaux de 
Paris, France 
QD, BID, TID 
nebulized 
colimycin 
(performed by 
vibrating plate 
nebulizer – 
aeroneb ® solo) 
+ intravenous 
placebo. Four 
million 
International 
Units of 
colistiimethate 
diluted in six ml 
of NaCl 0.9% 
solution are 
administered 
every eight 
hour. 
 
Nebulized 
placebo 
(performed by 
vibrating plate 
nebulizer – 
aeroneb ® solo) 
+ intravenous 
colimycin QD, 
BID, TID 
(according to 
renal function). 
A loading dose 
of six million 
international 
units (IU) of 
colistimethate 
sodium 
followed by 
maintenance 
dose of two 
million IU 
diluted in 50 
mof NaCl 0.9% 
solution, every 
eight hour is 
administered. 
 
Clinical cure of 
VAP caused by 
Gram-negative 
multidrug 
resistant  
bacteria 
(Pseudomonas 
aeruginosa 
resistive to 
aminoglycosides, 
cepholosporins, 
carbapenems 
and 
Acinetobacter 
baumanïi 
resistive to 
carnapenems). 
Microbiological 
cure rate , VAP 
recurrence rate, 
lung 
superinfection 
rate, mortality, 
duration of 
mechanical 
ventilation , 
length of ICU 
stay , renal 
function during 
colimycin 
administration , 
side effects 
resulting from 
colimycin 
nebulization , 
side effects 
resulting from 
colimycin 
intravenous 
administration, 
colistin plasma 
concentrations  
Quin Lu, 
Jean-
Jacques 
Rouby 
Effect of 
additional 
nebulized 
amikacin in 
ventilator-
associated 
pneumonia 
caused by Gram 
negative bacteria 
- NCT02574130 
Thammasat 
university , 
Thailand 
Nebulized 
amikacin (400 
mg BID for 10 
days) plus 
intravenous 
antibiotic(s)  
Nebulized 
placebo plus 
intravenous 
antibiotic(s) 
Cure rate  The reduction of 
pathogens 
(quantitative 
sputum culture), 
mortality rate, 
duration of 
mechanical 
ventilation, 
duration of ICU 
stay, duration of 
hospitalization, 
safety of 
intervention drug 
(any adverse 
effect). 
Pitchayapa 
Ruchiwit, 
Apichart 
Kanitsap 
Therapy of 
ventilator-
associated 
tracheobronchitis 
caused by Gram 
negative bacteria 
with nebulized 
colistin - 
NCT02619786 
Mahidol 
University, 
Thailand 
Inhaled colistin 
75 mg mixed 
with normal 
saline up to 4 
ml every 12 
hours at least 5 
days 
None Number of 
patients with 
cure, improved, 
failure or death  
Number of 
patients with 
eradication, 
persistence or 
superinfection; 
number of 
patients with 
grade 3 - 5 
adverse events 
that are related 
to study drug 
(NCI CTCAE 
version 3.0 ), 
grade 3 - 5 
adverse events 
related to study 
drug focus on 
neurology and 
bronchospasm. 
Adhiratha 
Boonyasiri 
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Title Sponsors - 
collaborators 
Intervention Comparator Primary outcome Secondary outcome
Amikacine nébulisée à forte dose. 
Pharmacocinétique dans la pneumonie 
associée à la ventilation mécanique 
D’ARTAGNAN 3 - 2008-000248-15 
Association pour la 
promotion de la 
réanimation 
médicale à Tours, 
France 
Nebulized 
Amikacin 60 – 
100 mg/kg 
Intravenous 
Amikacin 20 
mg/kg 
Dose of nebulized amikacin that 
allows to measure serum amikacin 
concentrations close to but inferior 
to those measured after standard 
intravenous amikacin infusion 
To evaluate safty of 
nebulized amikacin in 
intensive care unit patients. 
To evaluate de potential 
pulmonary and systemic 
accumulation of amikacin 
after repeated 
nebulizations. 
To evaluate the c
benefit of nebulized 
amikacine compared to 
intravenous infusion of 
amikacin. 
To modelize pulmonary 
absorption kinetics of 
nebulized amikacin. 
A Double-Blind, Placebo-Controlled, Parallel 
Group Phase 2 Dose-Ranging Study of 
Nebulized Amikacin Delivered Via the 
Pulmonary Drug Delivery System (PDDS) in 
Patients With Ventilator-Associated 
Pneumonia Due to Gram-Negative Organisms - 
2005-000060-16 
Aerogen, Inc. USA. Amikacin 
sulfate 125 
mg/ml 
Inhalation  
Placebo Proportion of patients in each arm 
who achieve a Cmax for amikacin 
in tracheal aspirates that is ≥25X 
the reference MIC for hospital-
acquired organisms, and an AUC(0-
24h)/MIC ≥ 100X on Day 1 
To assess the safety and 
tolerability of repeat doses 
pf aerosolized amikacin on 
ventilated patients o
duration of a course of 
therapy
 
 
 
 
 
